Description
Camizestrant (Etcamah®) is an orally administered, potent selective oestrogen receptor degrader (SERD) and complete oestrogen receptor (ER) α antagonist being developed by AstraZeneca for the treatment of breast cancer. It received its first approval in the United Arab Emirates (UAE) in May 2025. To date, the drug has been successively approved in Saudi Arabia, Japan, the European Union, Canada, the United Kingdom and the United States. Camizestrant has ultimately been approved for the treatment of adult patients with locally advanced or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer who have developed an ESR1 gene mutation during first-line hormone therapy; it is to be used in combination with a CDK4/6 inhibitor[2].